natgillin/translations-raw huggingface dataset:
Atazanavir plasma concentrations may decrease as a consequence of a reduction in cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance. 
Zbog sniženja plazmatskih koncentracija kobicistata mogu se sniziti i plazmatske koncentracije atazanavira, što za posljedicu može imati gubitak terapijskog učinka i razvoj rezistencije.
EVOTAZ should be used with caution in patients with mild hepatic impairment (see sections 4.2, 4.3 and 5.2). 
EVOTAZ treba primjenjivati uz oprez u bolesnika s blagim oštećenjem jetrene funkcije (vidjeti dijelove 4.2, 4.3 i 5.2).
Co-administration of EVOTAZ with proton pump inhibitors (PPIs) is not recommended due to the decreased solubility of atazanavir as intra-gastric pH increase with PPIs (see section 4.5). 
Ne preporučuje se istodobna primjena lijeka EVOTAZ s inhibitorima protonske pumpe jer se topljivost atazanavira smanjuje s povećanjem želučanog pH uzrokovanim primjenom inhibitora protonske pumpe (vidjeti dio 4.5).
Co-administration of tenofovir DF with cobicistat is expected to increase tenofovir plasma concentrations. 
Očekuje se da će istodobna primjena tenofovira DF i kobicistata povisiti plazmatske koncentracije tenofovira.
if you have type A or B haemophilia if you have problems with your kidneys or require haemodialysis. 
A ili B ako imate bubrežne tegobe koje zahtijevaju hemodijalizu.
Rifabutin 150 mg every other day/elvitegravir 150 mg once daily/cobicistat 150 mg once daily 
Rifabutin 150 mg svaki drugi dan/elvitegravir 150 mg jedanput na dan/kobicistat 150 mg jedanput na dan
Raltegravir 400 mg twice daily (atazanavir 400 mg) 
Raltegravir 400 mg dvaput na dan (atazanavir 400 mg)
(atazanavir 300 mg once daily with cobicistat 150 mg once daily) 
(atazanavir 300 mg jedanput na dan s kobicistatom 150 mg jedanput na dan)
Clinical monitoring may be needed upon co-administration with EVOTAZ. 
Možda će biti potrebno kliničko praćenje nakon istodobne primjene s lijekom EVOTAZ.
Cobicistat is a CYP3A substrate and is metabolised to a minor extent by CYP2D6. 
Kobicistat je supstrat za CYP3A i u manjoj se mjeri metabolizira putem CYP2D6.
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of atazanavir (see section 4.4). 
Kod primjene atazanavira prijavljeni su Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip praćen eozinofilijom i sistemskim simptomima (DRESS) (vidjeti dio 4.4).
If you develop signs or symptoms of kidney stones (pain in your side, blood in your urine, pain when you urinate), please inform your doctor immediately if you are taking oral contraceptives ("the Pill") to prevent pregnancy. 
Ako razvijete znakove ili simptome bubrežnih kamenaca (bol u slabinama, krv u mokraći, bol pri mokrenju), odmah o tome obavijestite svog liječnika.
Drospirenone/ethinyloestradiol 3 mg/0.02 mg single dose (atazanavir 300 mg once daily with cobicistat 150 mg once daily) 
Drospirenon/etinilestradiol 3 mg/0,02 mg u jednokratnoj dozi (atazanavir 300 mg jednom dnevno s kobicistatom150 mg jednom dnevno)
Co-administration of EVOTAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3). 
Istodobna primjena lijeka EVOTAZ s fiksnom kombinacijom glekaprevir/pibrentasvir je kontraindicirana zbog mogućeg povećanog rizika povišenja ALT-a zbog značajnog povišenja koncentracije glekaprevira i pibrentasvira u plazmi (vidjeti dio 4.3).
The effect of EVOTAZ on fertility in humans has not been studied. 
Nije ispitivan učinak lijeka EVOTAZ na plodnost ljudi.
No clinically relevant pharmacokinetic differences due to ethnicity have been identified for atazanavir or cobicistat. 
Nisu identificirane klinički značajne farmakokinetičke razlike uvjetovane etničkim podrijetlom koje bi bile povezane s atazanavirom ili kobicistatom.
There are limited data from the use of EVOTAZ in pregnant women. 
Podaci o primjeni lijeka EVOTAZ u trudnica su ograničeni.
Clinical monitoring of therapeutic effect and adverse events is recommended when these medicinal products are co-administered with EVOTAZ. 
Preporučuje se kliničko praćenje terapijskih učinaka i nuspojava pri istodobnoj primjeni navedenih lijekova s lijekom EVOTAZ.
Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily (atazanavir 400 mg once daily) 
Tenofovirdizoproksilfumarat (tenofovir DF) 300 mg jedanput na dan (atazanavir 400 mg jedanput na dan)
Omeprazole 40 mg once daily (atazanavir 400 mg once daily, 2 hours after omeprazole) 
Omeprazol 40 mg jedanput na dan (atazanavir 400 mg jedanput na dan, 2 sata nakon omeprazola)
Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation. 
Kobicistat se metabolizira oksidacijom u kojoj posreduju CYP3A (glavni put) i CYP2D6 (sporedni put) te ne prolazi glukuronidaciju.
14-OH clarithromycin Cmax ↓72% 
14-OH klaritromicin Cmax ↓72% (↓76%
The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole. 
Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuju atazanavir, kobicistat i ketokonazol ili itrakonazol.
Co-administration of EVOTAZ with voxilaprevir-containing products is expected to increase the concentration of voxilaprevir. 
Očekivano je da istodobna primjena lijeka EVOTAZ s lijekovima koji sadrže voksilaprevir povisi koncentraciju voksilaprevira.
Amiodarone Dronedarone Quinidine Systemic lidocaine 
Amiodaron Dronedaron Kinidin
Dose related asymptomatic prolongations in PR interval with atazanavir, a component of EVOTAZ have been observed in clinical studies. 
U kliničkim su ispitivanjima opažena asimptomatska produljenja PR-intervala povezana s dozom atanazavira, sastavnicom lijeka EVOTAZ.
Atazanavir and cobicistat are metabolised by the hepatic system. 
Atazanavir i kobicistat se metaboliziraju putem jetre.
Efavirenz 600 mg single dose (cobicistat 150 mg once daily) 
Efavirenz 600 mg u jednokratnoj dozi (kobicistat 150 mg jedanput na dan)
14-OH clarithromycin Cmin ↓62% 
14-OH klaritromicin Cmin ↓62% (↓66%
Nephrolithiasis has been reported in patients receiving atazanavir (see section 4.8). 
U bolesnika koji su primali atazanavir prijavljena je nefrolitijaza (vidjeti dio 4.8).
Cobicistat is a selective, mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. 
Kobicistat je selektivni inhibitor citokroma P450 podobitelji CYP3A temeljeno na mehanizmu.
Didanosine (enteric coated capsules) 400 mg single dose (atazanavir 400 mg once daily) 
Didanozin (želučanootporne kapsule) 400 mg u jednokratnoj dozi (atazanavir 400 mg jedanput na dan)
Co-administration of salmeterol with EVOTAZ is not recommended (see section 4.4). 
Ne preporučuje se istodobna primjena salmeterola i lijeka EVOTAZ (vidjeti dio 4.4).
Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening adverse reactions. 
Istodobna primjena s lijekom EVOTAZ može uzrokovati ozbiljne i/ili po život opasne nuspojave.
Cobicistat, a component of EVOTAZ, has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine. 
Pokazalo se da kobicistat, sastavnica lijeka EVOTAZ, smanjuje procijenjeni klirens kreatinina zbog inhibicije tubularne sekrecije kreatinina.
AUC ↑247% (↑229% ↑267%) Cmax ↑216% (↑200% ↑233%) Cmin ↑273% (↑254% ↑293%) 
AUC ↑247% (↑229% ↑267%) Cmax ↑216% (↑200% ↑233%)
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may result in increased plasma concentration of atazanavir and/or cobicistat. 
Istodobna primjena lijeka EVOTAZ i lijekova koji inhibiraju CYP3A može povisiti plazmatske koncentracije atazanavira i/ili kobicistata.
Naloxone AUC: ↓28% Naloxone Cmax: ↓28% 
Nalokson AUC: ↓28% Nalokson Cmax: ↓28%
gait disturbance (abnormal manner of walking) oedema (swelling), palpitation (fast or irregular heart beat) hepatosplenomegaly (enlargement of the liver and spleen) vesiculobullous rash (visible accumulation of fluid under the skin), eczema (skin rash), vasodilatation (widening of blood vessels) 
Rijetke (mogu se javiti u do 1 na 1000 osoba) produljenje QTc-intervala (nepravilan srčani ritam) poremećaj hoda (neuobičajen način hodanja) edem (oticanje), palpitacije (ubrzan ili nepravilan srčani ritam) hepatosplenomegalija (povećanje jetre i slezene) vezikulobulozni osip (vidljivo nakupljanje tekućine pod kožom), ekcem (kožni osip), vazodilatacija (proširenje krvnih žila)
Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir 
Koncentracije elbasvira bile su povišne s istodobnom primjenom atazanavira/ritonavira
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients receiving atazanavir. 
U bolesnika koji su primali atazanavir prijavljeni su Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip praćen eozinofilijom i sistemskim simptomima (engl. drug rash with eosinophilia and systemic symptoms, DRESS).
Co-administration of EVOTAZ and nevirapine is not recommended and may result in a loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir. 
Ne preporučuje se istodobna primjena lijeka EVOTAZ i nevirapina jer može dovesti do gubitka terapijskog učinka lijeka EVOTAZ i razvoja rezistencije na atazanavir.
Hepatobiliary disorders very common jaundice common hyperbilirubinaemia uncommon hepatitis, cholelithiasisa, cholestasisa rare hepatosplenomegaly, cholecystitisa 
Poremećaji jetre i žuči vrlo često žutica često hiperbilirubinemija manje često hepatitis, kolelitijazaa, kolestazaa rijeko hepatosplenomegalija, kolecistitisa
Co-administration of tenofovir alafenamide with cobicistat is expected to increase tenofovir alafenamide and tenofovir plasma concentrations. 
Pri istodobnoj primjeni tenofoviralafenamida s kobicistatom, očekuju se povećane koncentracije tenofoviralafenamida i tenofovira u plazmi.
ACID REDUCING AGENTS 
LIJEKOVI ZA SMANJENJE KOLIČINE ŽELUČANE KISELINE
More frequent therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with EVOTAZ. 
Preporučuje se učestalija kontrola terapijskih koncentracija imunosupresiva pri njihovoj istodobnoj primjeni s lijekom EVOTAZ.
Studies in animals have been shown excretion of cobicistat/metabolites in milk Because of both the potential for HIV transmission and the potential for serious adverse reactions in breast-feeding infants, women should be instructed not to breast-feed if they are receiving EVOTAZ. 
Zbog mogućnosti prijenosa HIV-a na dojenčad i pojave ozbiljnih nuspojava u dojenčadi, žene treba uputiti da ne doje ako primaju EVOTAZ.
Co-administration of etravirine and EVOTAZ is expected to decrease atazanavir and cobicistat plasma concentrations. 
Očekuje se da će istodobna primjena etravirina i lijeka EVOTAZ sniziti plazmatske koncentracije atazanavira i kobicistata.
300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil. 
245 mg tenofovirdizoproksila.
Cholelithiasis has been reported in patients receiving atazanavir (see section 4.8). 
U bolesnika koji su primali atazanavir prijavljena je kolelitijaza (vidjeti dio 4.8).
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors. 
Mehanizam interakcije je smanjena topljivost atazanavira zbog povišenog želučanog pH koji uzrokuju inhibitori protonske pumpe.
Co-administration of EVOTAZ with astemizole and terfenadine is contraindicated (see section 4.3). 
Istodobna primjena lijeka EVOTAZ s astemizolom i terfenadinom je kontraindicirana (vidjeti dio 4.3).
The mechanism is UGT1A1 inhibition by atazanavir. 
Mehanizam je inhibicija UGT1A1 koju uzrokuje atazanavir.
The mechanism of interaction is inhibition of CYP3A4 and/or CYP2D6 by atazanavir and/or cobicistat. 
Mehanizam interakcije je inhibicija CYP3A4 i/ili CYP2D6 koju uzrokuju atazanavir i/ili kobicistat.
Co-administration of EVOTAZ and elbasvir/grazoprevir is contraindicated because of the expected increase in grazoprevir plasma concentrations and the associated potential increase in the risk of ALT elevations (see section 4.3). 
Istodobna primjena lijeka EVOTAZ s elbasvirom/grazoprevirom je kontraindicirana zbog očekivanog povišenja koncentracije grazoprevira u plazmi, te povezanim mogućim povećanim rizikom povišenja ALT-a (vidjeti dio 4.3).
Telaprevir 750 mg three times daily (atazanavir/ritonavir 300/100 mg once daily) 
Telaprevir 750 mg triput na dan (atazanavir/ritonavir 300/100 mg jedanput na dan)
GASTROINTESTINAL MOTILITY AGENTS Cisapride 
LIJEKOVI ZA MOTILITET PROBAVNOG SUSTAVA Cisaprid
Voxilaprevir AUC : ↑331% 
Voksilaprevir AUC: ↑331% (↑276%
The combination of rifampicin and EVOTAZ is contraindicated (see section 4.3). 
Kombinacija rifampicina i lijeka EVOTAZ je kontraindicirana (vidjeti dio 4.3).
EVOTAZ is not recommended in patients undergoing haemodialysis (see sections 4.2 and 5.2). 
Primjena lijeka EVOTAZ ne preporučuje se u bolesnika na hemodijalizi (vidjeti dijelove 4.2 i 5.2).
Buprenorphine, once daily, stable maintenance dose (atazanavir 300 mg once daily with ritonavir 100 mg once daily) 
Buprenorfin, jedanput na dan, stabilna doza održavanja (atazanavir 300 mg jedanput na dan i ritonavir 100 mg jedanput na dan)
Coadministration of EVOTAZ with voxilaprevir-containing regimens is not recommended. 
Ne preporučuje se istodobna primjena lijeka EVOTAZ s režimima koji uključuju voksilaprevir.
Glecaprevir 300 mg/pibrentasvir 120 mg once daily (atazanavir 300 mg with ritonavir 100 mg once daily*) 
Glekaprevir 300 mg/pibrentasvir 120 mg jednom dnevno (atazanavir 300 mg s ritonavirom 100 mg jednom dnevno*)
Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir) are observed on co-administration with cobicistat. 
Kod istodobne primjene s kobicistatom primijećene su povišene plazmatske koncentracije lijekova koji se metaboliziraju putem CYP3A (uključujući atazanavir).
Tell your doctor if you notice anything unusual about your health. 
Ako primijetite bilo što neobično u vezi sa svojim zdravljem, obavijestite o tome svog liječnika.
EVOTAZ is not recommended for co-administration with etravirine because it may result in the loss of therapeutic effect and development of resistance to atazanavir. 
Ne preporučuje se istodobna primjena lijeka EVOTAZ i etravirina jer može dovesti do gubitka terapijskog učinka lijeka EVOTAZ i razvoja rezistencije na atazanavir.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers. 
Mehanizam interakcije je smanjena topljivost atazanavira zbog povišenog želučanog pH koji uzrokuju blokatori H2-receptora.
Atazanavir with cobicistatf (n = 344) 
144. tjedan Atazanavir s Atazanavir s Atazanavir s Atazanavir s kobicistatomf (n = 344)
The mechanism of interaction is CYP3A4 induction by rifampicin. 
Mehanizam interakcije je indukcija CYP3A4 koju uzrokuje rifampicin.
The combination of pimozide, quetiapine or lurasidone and EVOTAZ is contraindicated (see section 4.3). 
Kombinacija pimozida kvetiapina ili lurasidona s lijekom EVOTAZ je kontraindicirana (vidjeti dio
Hyperbilirubinaemia (an increase in the level of bilirubin in the blood) has occurred in patients receiving EVOTAZ. 
U bolesnika koji uzimaju EVOTAZ može se razviti hiperbilirubinemija (povišena razina bilirubina u krvi).
No significant effect on methadone concentrations was observed when co-administered with atazanavir. 
Nisu opaženi značajni učinci na koncentraciju metadona kod istodobne primjene s atazanavirom.
substrates of CYP3A4 or the UGT1A1 isoform of UDP-glucuronyltransferase and have narrow therapeutic windows: alfuzosin (alpha-1-adrenoreceptor antagonist) amiodarone, bepridil, dronedarone, quinidine, systemic lidocaine (antiarrhythmics/antianginals) astemizole, terfenadine (antihistamines) cisapride (gastrointestinal motility agent) ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) pimozide, quetiapine, lurasidone (antipsychotics/neuroleptics) (see section 4.5) ticagrelor (platelet aggregation inhibitor) triazolam, midazolam administered orally (sedatives/hypnotics) (for caution on parenterally administered midazolam, see section 4.5). 
lijekove koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvir/grazoprevir (koja se koristi u liječenju kronične infekcije virusom hepatitisa C) (vidjeti dio 4.5) glekaprevir/pibrentasvir fiksna kombinacija (vidjeti dio 4.5) supstrati za CYP3A4 ili izooblik UGT1A1 UDP-glukuroniltransferaze koji imaju uzak terapijski raspon: alfuzosin (antagonist alfa-1-adrenoreceptora) amiodaron, bepridil, dronedaron, kinidin, sistemski lidokain (antiaritmici/antianginici) astemizol, terfenadin (antihistaminici) cisaprid (lijek za motilitet probavnog sustava) derivati ergota (npr. dihidroergotamin, ergometrin, ergotamin, metilergonovin) pimozid, kvetiapin, lurasidon (antipsihotici/neuroleptici) (vidjeti dio 4.5) tikagrelor (inhibitor agregacije trombocita) triazolam, peroralno primijenjen midazolam (sedativi/hipnotici) (za mjere opreza kod parenteralne primjene midazolama vidjeti dio 4.5).
People who already have type A or B haemophilia may notice increased bleeding. 
A ili B mogu primijetiti pojačano krvarenje.
Cobicistat Cobicistat has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). 
Kobicistat nije ispitivan u bolesnika s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C).
Efavirenz 600 mg once daily (atazanavir 400 mg once daily) 
Efavirenz 600 mg jedanput na dan (atazanavir 400 mg jedanput na dan)
EVOTAZ is not recommended for patients undergoing haemodialysis (see sections 4.4 and 5.2). 
Primjena lijeka EVOTAZ ne preporučuje se u bolesnika na hemodijalizi (vidjeti dijelove 4.4 i 5.2).
Careful patient monitoring and dose adjustment of metformin is recommended in patients who are taking EVOTAZ. 
U bolesnika koji uzimaju EVOTAZ preporučuje se pažljivo praćenje bolesnika i prilagodba doze metformina.
The mechanism of interaction is CYP3A4 and UGT1A1 inhibition by atazanavir. 
Mehanizam interakcije je inhibicija CYP3A4 i UGT1A1 koju uzrokuje atazanavir.
The mechanism of interaction is inhibition of P-gp by cobicistat. 
Mehanizam interakcije je inhibicija Pgp-a koju uzrokuje kobicistat.
For more information consult the REYATAZ Summary of Product Characteristics. 
Za više informacija, pročitajte Sažetak opisa svojstava lijeka za REYATAZ.
Drug interaction trials were not conducted for EVOTAZ. 
Nisu provedena ispitivanja interakcija lijeka EVOTAZ s drugim lijekovima.
Clinical monitoring is recommended upon co-administration with EVOTAZ. 
Preporučuje se kliničko praćenje nakon istodobne primjene s lijekom EVOTAZ.
The mechanism of interaction is inhibition of UGT1A1 by atazanavir. 
Mehanizam interakcije je inhibicija UGT1A1 koju uzrokuje atazanavir.
Concomitant use of St. John's wort with EVOTAZ may be expected to result in significant reduction in plasma levels of cobicistat and atazanavir. 
Može se očekivati da će istodobna primjena gospine trave i lijeka EVOTAZ značajno sniziti plazmatske razine kobicistata i atazanavira.
The mechanism of interaction is CYP3A and/or P-glycoprotein inhibition by atazanavir and cobicistat. 
Mehanizam interakcije je inhibicija CYP3A i/ili P-glikoproteina koju uzrokuju atazanavir i kobicistat.
The mechanism of interaction is CYP3A4 induction by nevirapine and CYP3A4 inhibition by atazanavir and cobicistat. 
Mehanizam interakcije je indukcija CYP3A4 koju uzrokuje nevirapin i inhibicija CYP3A4 koju uzrokuju atazanavir i kobicistat.
Co-administration of voriconazole and EVOTAZ is not recommended unless an assessment of the benefit/risk justifies the use of voriconazole (see section 4.5). 
Ne preporučuje se istodobna primjena vorikonazola i lijeka EVOTAZ, osim u slučajevima kada procjena omjera koristi i rizika opravdava primjenu vorikonazola (vidjeti dio 4.5).
System Organ Class Frequency 
Organski sustav Učestalost
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 300 mg of atazanavir (as sulphate) and 150 mg of cobicistat. 
2. NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 300 mg atazanavira (u obliku atazanavirsulfata) i 150 mg kobicistata.
Lamivudine 150 mg twice daily + zidovudine 300 mg twice daily (atazanavir 400 mg once daily) 
Lamivudin 150 mg dvaput na dan + zidovudin 300 mg dvaput na dan (atazanavir 400 mg jedanput na dan)
Concentration of fluconazole may be increased if co-administered with cobicistat. 
Koncentracije flukonazola mogu porasti kod istodobne primjene s kobicistatom.
Exposure to diltiazem and a metabolite, desacetyl-diltiazem, is increased when diltiazem is co-administered with atazanavir, a component of EVOTAZ. 
Kod istodobne primjene s atazanavirom, sastavnicom lijeka EVOTAZ, povećava se izloženost diltiazemu i jednom njegovom metabolitu, dezacetil-diltiazemu.
Adverse Reactions uncommon myalgia, muscle atrophy, arthralgia rare myopathy 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva manje često mialgija, mišićna atrofija, artralgija rijeko miopatija
EVOTAZ is expected to increase simeprevir plasma concentrations. 
Očekuje se da će EVOTAZ povisiti plazmatske koncentracije simeprevira.
Co-administration of EVOTAZ and these antiepileptics is contraindicated (see section 4.3). 
Istodobna primjena lijeka EVOTAZ i navedenih epileptika je kontraindicirana (vidjeti dio 4.3).
Stevens-Johnson syndrome (allergic reactions including serious skin rash, a high temperature and enlarged lymph nodes) (see section 2). 
Stevens-Johnsonov sindrom (alergijske reakcije, uključujući ozbiljan kožni osip, povišenu tjelesnu temperaturu i povećane limfne čvorove) (vidjeti dio 2.) miopatija (bolni mišići, osjetljivost mišića na dodir ili slabost mišića koja nije posljedica tjelovježbe) bol u bubrezima
Dihydroergotamine Ergometrine Ergotamine Methylergonovine 
Dihidroergotamin Ergometrin Ergotamin Metilergonovin
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors. 
U bolesnika s hemofilijom A i B liječenih inhibitorima proteaze prijavljeni su slučajevi pojačanog krvarenja, uključujući spontani nastanak kožnih hematoma i hemartroze.
The mechanism of interaction is CYP3A4 induction by etravirine. 
Mehanizam interakcije je indukcija CYP3A4 koju uzrokuje etravirin.
Renal and urinary disorders uncommon nephrolithiasisa, haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney diseasea rare kidney pain 
Poremećaji bubrega i mokraćnog sustava manje često nefrolitijazaa, hematurija, proteinurija, polakizurija; intersticijski nefritis, kronična bubrežna bolesta rijeko bol u bubrezima
Elbasvir 50 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily 
Elbasvir 50 mg jedanput na dan (atazanavir 300 mg / ritonavir 100 mg jednom dnevno
Cobicistat: 
Kobicistat:
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. 
Budući da se očekuje povećana izloženost rifabutinu, potreban je pojačan nadzor zbog mogućih nuspojava povezanih s rifabutinom, uključujući neutropeniju i uveitis.
The mechanism of interaction is induction of CYP3A4 by bosentan. 
Mehanizam interakcije je indukcija CYP3A4 koju uzrokuje bosentan.
The mechanism of interaction is CYP3A4 and P-gp inhibition by cobicistat. 
Mehanizam interakcije je inhibicija CYP3A4 i P-gp-a koju uzrokuje kobicistat.
A decrease in the dose of neuroleptics metabolized by CYP3A or CYP2D6 may be required when co-administered with EVOTAZ. 
Kod istodobne primjene s lijekom EVOTAZ možda će trebati smanjiti dozu neuroleptika koji se metaboliziraju putem enzima CYP3A ili CYP2D6.
Co-administration of EVOTAZ and indinavir is not recommended (see section 4.4). 
Ne preporučuje se istodobna primjena lijeka EVOTAZ s indinavirom (vidjeti dio 4.4).